Non-small Cell Lung Cancer Cells Modulate the Development of Human CD1c⁺ Conventional Dendritic Cell Subsets Mediated...

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Advanced non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality.
• NSCLC establishes an immune-suppressive microenvironment, facilitating immune evasion.
• The precise molecular mechanisms underlying NSCLC immunopathogenesis remain incompletely understood.

Purpose of the Study:

• To investigate the influence of NSCLC cells on the development and differentiation of human CD1c+ dendritic cell (DC) subsets.
• To elucidate the roles of CD205 and CD103 in NSCLC-mediated modulation of DCs.
• To identify potential cellular targets for enhancing anti-tumor immunity in NSCLC.

Main Methods:

• Peripheral blood mononuclear cells (PBMCs) were isolated from NSCLC patients and healthy donors.
• Dendritic cells (DCs) were induced and co-cultured with primary NSCLC cells or the H1299 cell line.
• Flow cytometry was used to analyze the expression of key molecules (e.g., CD80, CD86, HLA-DR, IL-10, IL-12, CD205, CD103) on CD1c+ DCs.

Main Results:

• Two novel human CD1c+ DC subpopulations, CD1c+CD205+CD103+ and CD1c+CD205+CD103- DCs, were identified in both healthy donors and NSCLC patients.
• NSCLC cells were found to modulate the development of these CD1c+ DC subpopulations both in vitro and ex vivo.
• NSCLC cells suppressed co-stimulatory molecules (CD40, CD80, CD86, HLA-DR) and pro-inflammatory cytokines (IL-12, IL-23) while upregulating anti-inflammatory cytokines (IL-10, IL-27) in CD1c+ DCs.

Conclusions:

• NSCLC cells induce tolerogenic CD1c+ DCs, which may inhibit DC-mediated anti-tumor immunity.
• These findings reveal novel cellular mechanisms contributing to the immune-suppressive microenvironment in NSCLC.
• Targeting CD1c+ DC subsets mediated by CD205 and CD103 presents a potential future immunotherapy strategy for NSCLC.